The fight against respiratory syncytial virus (RSV), a leading cause of infant hospitalization worldwide, has seen remarkable advances with novel vaccines and monoclonal antibodies. Newly approved single-dose antibody therapies like Sanofi and AstraZeneca’s nirsevimab offer broader coverage beyond high-risk infants. Indigenous communities facing disproportionate RSV burdens are benefiting from culturally grounded public health initiatives. Ongoing developments in RSV immunity and prevention promise to reduce severe infant illness and deaths globally.